Year: 2023

DURHAM, N.C., Nov. 07, 2023 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or “the Company”), a global leader in innovations for active healing, today reported financial results for the three and nine months ended September 30, 2023. Q3 Financial Summary:Net Sales of $120.8 million, down $7.9 million, or 6.1%, year-over-year as reported (6.3% constant currency*). Excluding revenues from divested wound assets, underlying organic sales decreased $0.6 million, or 0.5% year-over-year Net Loss from continuing operations of $8.8 million, compared to Net Loss from continuing operations of $101.0 million in prior-year period Adjusted EBITDA* from continuing operations of $21.7 million decreased (0.9%), compared to $21.9 million in prior-year period Loss per share of Class A common stock from continuing...

Delivers 15% Revenue Growth on Strength of Recorded Music Raises Fiscal 2024 Full-Year Top-Line and Profitability Guidance NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) — Reservoir Media, Inc. (NASDAQ: RSVR) (“Reservoir” or the “Company”), an award-winning independent music company, today announced financial results for the second fiscal quarter of 2024 ended September 30, 2023. Recent Highlights:Revenue of $38.4 million, increased 10% organically, or 15% including acquisitions year-over-yearMusic Publishing revenue rose 8% year-over-year Recorded Music revenue increased by 22% year-over-yearOperating Income of $6.1 million, decreased by $0.4 million year-over-year OIBDA (“Operating Income Before Depreciation & Amortization”) of $12.4 million, an increase of 3% year-over-year Net Income of $0.7 million, or $0.01 per share,...

Q3 Revenues of $25.4 million Q3 Gross Margin of 58.1% Q3 GAAP operating loss of $0.9 million, adjusted operating income $1.8 million Continued strong operating cash flow drove debt reduction of $8.3 million through Q3HOLLISTON, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) — Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the third quarter ended September 30, 2023. Jim Green, Chairman and CEO said, “Overall, I’m encouraged to see solid year-over-year third quarter revenue growth in North America in a quarter that had significant headwinds in Asia. Third quarter revenues also included a net reduction of $1.3 million from discontinued products compared to the third quarter of last year. Our improved portfolio is driving significant gross margin expansion.” Green continued, “We remain focused...

VANCOUVER, British Columbia, Nov. 07, 2023 (GLOBE NEWSWIRE) — Endeavour Silver Corp. (“Endeavour” or the “Company”) (NYSE: EXK; TSX: EDR) announces its unaudited financial and operating results for the three and nine months ended September 30, 2023. All amounts reported are in United States (US) dollars. “Our third quarter was challenging on a number of fronts, marking the lowest quarterly production for the Company in over two years. We were negatively impacted by several factors, however reduced productivity at Guanacevi is what led to a production shortfall. This reduced productivity was the result of mine sequencing changes that were initiated to improve access and ventilation, which have resulted in a significant reduction in ore grades. These lower silver and gold grades, combined with lower precious metals prices, a stronger...

Oral arguments in appeal of ‘793 PTAB decision set for December 4, 2023 PDUFA goal date to add PH-ILD indication to YUTREPIA label is January 24, 2024 Hired sales force in preparation of potential positive legal and regulatory outcomesMORRISVILLE, N.C., Nov. 07, 2023 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today reported financial results for the third quarter ended September 30, 2023. The Company will host a webcast at 8:30 a.m. ET to discuss the financial results and provide a corporate update. Dr. Roger Jeffs, Liquidia’s Chief Executive Officer, said: “We continue to make great strides in advancing our mission to help patients with pulmonary hypertension breathe easier and live longer. We are looking forward to upcoming key events that will help unlock the value of YUTREPIA® (treprostinil)...

NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) — Outbrain Inc. (Nasdaq: OB), a leading technology platform that drives business results by engaging people across the open Internet, announced today financial results for the quarter ended September 30, 2023. “First we want to address the situation in the Middle East and express our support to the people of Israel and our employees and their families,” said David Kostman and Yaron Galai, Outbrain’s Co-CEOs. “We are pleased with the year over year growth of 8% in our Ex-TAC gross profit, finishing Q3 within the range of our guidance, while significantly exceeding the high end of our Adjusted EBITDA guidance and generating positive free cash flow,” said David Kostman. “In light of the macroeconomic volatility and geopolitical challenges we continue with our cost discipline, while remaining...

U.S. Food and Drug Administration (FDA) Clears Investigational New Drug Application for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia (HeFH) Collaboration with Eli Lilly and Company (Lilly) Expands Through Lilly’s Acquisition of Product Rights to Verve’s PCSK9 and ANGPTL3 Programs from Beam Therapeutics Interim Data from the heart-1 Phase 1b Clinical Trial of VERVE-101 in Patients with HeFH to be Presented at the American Heart Association (AHA) Scientific Sessions 2023 on November 12 at 3:30 p.m. ET; Company to Host Investor Event and Webcast on November 12 at 6:30 p.m. ET Cash, Cash Equivalents and Marketable Securities of $485.2 Million with Cash Runway into 2026 BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) — Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care...

Record results on growth acceleration, significant improvement in operating loss and cash burn BOSTON and ROLLE, Switzerland, Nov. 07, 2023 (GLOBE NEWSWIRE) — SOPHiA GENETICS SA (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today reported financial results for the third quarter ended September 30, 2023. Recent HighlightsRevenue for the third quarter of 2023 was $16.3 million, representing year-over-year growth of 40% on a reported basis over the corresponding period of 2022; Constant currency year-over-year revenue growth excluding COVID-19-related revenues was 37%. Gross margins were 69% on a reported basis and 73% on an adjusted basis for the third quarter of 2023. Operating loss in the third quarter of 2023 was $16.5 million on a reported basis and $11.8 million on an adjusted basis,...